Abbott Laboratories (ABT) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Total Assets Chart for Abbott Laboratories
Abbott Laboratories (ABT) total assets for FY2025 were USD 86.7B, a 6.5% change from FY2024. Abbott Laboratories's total assets grew from USD 3.5B in 1985 to USD 86.7B in 2025 (2400.1% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 3.6%, 10-year CAGR of 7.0%, 20-year CAGR of 5.6%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $186.81B
- Implied Share Price
- $107.96
- Enterprise Value
- $209.91B
- Revenue (TTM)
- $46.58B
- EBITDA
- $11.68B
- Profit Margin
- 11.65%
- Trailing P/E
- 34.27
- Forward P/E
- 19.16
- Price/Book (MRQ)
- 3.58
- Price/Sales (TTM)
- 4.04
- EV/EBITDA
- 17.91
- EV/Revenue
- 4.51
- Dividend Yield
- 2.35%
- Book Value
- $29.54
- Free Cash Flow (FY2025)
- $7.39B
- Free Cash Flow Yield
- 3.96%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.